Skip Surgery for DCIS in Favor of Active Monitoring?
SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ...
Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk Patients
The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related cardiovascular (CV) events ...
New Investigation Casts Doubt on Landmark Ticagrelor Trial
New questions about the landmark trial that launched the antiplatelet drug ticagrelor worldwide are being raised after an investigation uncovered ...
Doc Confesses to Killing Wife, Police Say; Nurse Reprimanded for Cursing at Toddler
Orlando-area physician Thomas Wentzell, MD, was arrested and confessed to killing his wife, according to local police. (WFTV9) Twenty lawsuits ...
The 7 Biggest Financial Enemies of Doctors
Success in personal finance and reaching financial freedom is not complicated. But that does not mean it is necessarily easy ...
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
One of the most meaningful shifts in the cancer treatment landscape has been the move toward therapies that not only ...
Benefits and Risks of the Viral Workout
Share on PinterestThe 12-3-30 treadmill challenge is trending on TikTok, but can the viral workout really help you lose weight? ...
FDA Issues Safety Alert on Liver Disease Drug
Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without ...
Are Schools Shifting From Drug Prevention to Mental Health?
TOPLINE:From 2008 to 2020, US schools reported significant increases in emotional/mental health education (from 83.8% to 89.8%) and suicide prevention ...
Providers, You Are the Missing Piece: Your Patients With OUD Need You
Califf is FDA commissioner. Sokolowska is an FDA deputy center director specializing in substance use and behavioral health. As of ...
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer
The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as ...
First final compensation in blood scandal to be paid in days
The government has said the first victims of the infected blood scandal will receive final compensation payments this week. Ten ...
Pulled Myeloma Drug Improves Survival in Trial
SAN DIEGO -- A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of ...
Should Hospitals Be Paid the Same as Doctors’ Offices for the Same Service?
The idea of requiring site-neutral payments in Medicare -- in which providers would be reimbursed at the same rate for ...
More CEOs Targeted in Wanted Posters; Ultraprocessed Food Lawsuit; OD Deaths Fall
Note that some links may require registration or subscription. "Wanted" posters of healthcare CEOs were put up in New York ...
Mystery Disease in Congo May Be Malaria but More Testing Needed, Authorities Say
The mystery flu-like illness that killed dozens of people in southwest Congo in recent weeks might be malaria, according to ...
Whistleblower Doc Sues Hospital, Claims Retaliation
Cardiologist Daniel West, MD, had practiced at Trinity Health Muskegon Hospital, Muskegon, Mich., since he finished medical school. His mother ...
Diabetes Drugs and Eye Disease: These Protect, These Don’t
TOPLINE:Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) ...
General Practitioners and Specialists: What’s a Fair Price?
During the first congress of the Belgian College of General Practitioners, held on November 15 and 16 in Namur, Belgium, ...
Could Covering GLP-1s Pay Off?
The question may seem simple: Could paying for weight loss medications — especially the pricey glucagon-like peptide 1 receptor agonists ...
